Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.
Gschwantler M, Laferl H, Vogel W, Korak W, Moser S, Hofer H, Bauer B, Schleicher M, Bognar B, Bischof M, Stauber R, Maieron A, Ferenci P; Austrian Hepatitis Study Group. Gschwantler M, et al. Wien Klin Wochenschr. 2018 Jan;130(1-2):54-61. doi: 10.1007/s00508-017-1263-2. Epub 2017 Sep 12. Wien Klin Wochenschr. 2018. PMID: 28900714
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Gangl A, Vogel W; Austrian Hepatitis Study Group. Steindl-Munda P, et al. Among authors: gschwantler m. Liver Int. 2003 Aug;23(4):269-75. doi: 10.1034/j.1600-0676.2003.00838.x. Liver Int. 2003. PMID: 12895267 Clinical Trial.
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: gschwantler m. J Hepatol. 2006 Feb;44(2):275-82. doi: 10.1016/j.jhep.2005.09.015. Epub 2005 Nov 7. J Hepatol. 2006. PMID: 16338019 Clinical Trial.
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: gschwantler m. Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262. Hepatology. 2008. PMID: 18454510 Clinical Trial.
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: gschwantler m. Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27. Gastroenterology. 2008. PMID: 18503773 Clinical Trial.
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group. Ferenci P, et al. Among authors: gschwantler m. Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10. Gastroenterology. 2010. PMID: 19909752 Clinical Trial.
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M. Moser S, et al. Among authors: gschwantler m. Eur J Gastroenterol Hepatol. 2018 Mar;30(3):291-295. doi: 10.1097/MEG.0000000000001027. Eur J Gastroenterol Hepatol. 2018. PMID: 29120906
Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.
Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer TM, Strassl R, Holzmann H, Steindl-Munda P, Ferenci P. Rutter K, et al. Among authors: gschwantler m. Aliment Pharmacol Ther. 2013 Jul;38(2):118-23. doi: 10.1111/apt.12350. Epub 2013 May 26. Aliment Pharmacol Ther. 2013. PMID: 23710895 Free article.
Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Kozbial K, et al. Among authors: gschwantler m. Liver Int. 2018 Jun;38(6):1028-1035. doi: 10.1111/liv.13629. Epub 2017 Dec 1. Liver Int. 2018. PMID: 29136329
143 results